If insiders don't buy, show them the doorAnd the first one out should be Gilles Gagnon because the buck stops at the top. Gagnon's biggest blunder was the new facility build - years late and way over-budget. And now that CZO has 10x the contract manufacturing capacity, Gilles decides that the company is going to shift away from contract manufacturing to focus instead on biopharma opportunities.
The consequences of that shift are reflected in the stock performance. Instead of sticking to its knitting and growing its core competence, CZO has lost its focus and squandered the opportunity to fully leverage new plant.
I'm going to repeat myself until CZO moves to replace leadership: GILLES GAGNON must GO!
At that point, we can also sever ties with the completely useless Jenene Thomas, who is over-paid in US dollars.